Literature DB >> 26417178

Researchers Expand Focus on Progressive Forms Of Multiple Sclerosis: Efforts to Pinpoint the Beginning of Disease May Yield Clues to Treatment.

Susan Worley.   

Abstract

With disease-modifying treatments available for relapsing-remitting multiple sclerosis (MS), the quest for therapies for progressive MS has become a key focus of research.

Entities:  

Year:  2015        PMID： 26417178      PMCID： PMC4571847     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  23 in total

Review 1.  No quiet surrender: molecular guardians in multiple sclerosis brain.

Authors:  Lawrence Steinman
Journal:  J Clin Invest       Date:  2015-04-01       Impact factor: 14.808

2.  Multiple sclerosis: Spinal cord grey matter loss correlates with disability in MS.

Authors:  Hemi Malkki
Journal:  Nat Rev Neurol       Date:  2014-08-26       Impact factor: 42.937

3.  Spinal cord grey matter abnormalities are associated with secondary progression and physical disability in multiple sclerosis.

Authors:  H Kearney; T Schneider; M C Yiannakas; D R Altmann; C A M Wheeler-Kingshott; O Ciccarelli; D H Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-08-05       Impact factor: 10.154

4.  Patients report worse MS symptoms after menopause: findings from an online cohort.

Authors:  R Bove; B C Healy; E Secor; T Vaughan; B Katic; T Chitnis; P Wicks; P L De Jager
Journal:  Mult Scler Relat Disord       Date:  2014-12-09       Impact factor: 4.339

5.  Spinal cord gray matter atrophy correlates with multiple sclerosis disability.

Authors:  Regina Schlaeger; Nico Papinutto; Valentina Panara; Carolyn Bevan; Iryna V Lobach; Monica Bucci; Eduardo Caverzasi; Jeffrey M Gelfand; Ari J Green; Kesshi M Jordan; William A Stern; H-Christian von Büdingen; Emmanuelle Waubant; Alyssa H Zhu; Douglas S Goodin; Bruce A C Cree; Stephen L Hauser; Roland G Henry
Journal:  Ann Neurol       Date:  2014-08-21       Impact factor: 10.422

Review 6.  Pathological mechanisms in progressive multiple sclerosis.

Authors:  Don H Mahad; Bruce D Trapp; Hans Lassmann
Journal:  Lancet Neurol       Date:  2015-02       Impact factor: 44.182

Review 7.  Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab.

Authors:  Caroline Antoniol; Bruno Stankoff
Journal:  Front Immunol       Date:  2015-01-05       Impact factor: 7.561

8.  Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Tatiana Plavina; Meena Subramanyam; Gary Bloomgren; Sandra Richman; Amy Pace; Sophia Lee; Brian Schlain; Denise Campagnolo; Shibeshih Belachew; Barry Ticho
Journal:  Ann Neurol       Date:  2014-10-24       Impact factor: 10.422

Review 9.  Alemtuzumab for the treatment of multiple sclerosis.

Authors:  Mark D Willis; Neil P Robertson
Journal:  Ther Clin Risk Manag       Date:  2015-03-31       Impact factor: 2.423

10.  The discovery of natalizumab, a potent therapeutic for multiple sclerosis.

Authors:  Lawrence Steinman
Journal:  J Cell Biol       Date:  2012-10-29       Impact factor: 10.539
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.